GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Cyclically Adjusted PB Ratio

XNCR (Xencor) Cyclically Adjusted PB Ratio : 0.75 (As of May. 30, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Cyclically Adjusted PB Ratio?

As of today (2025-05-30), Xencor's current share price is $8.00. Xencor's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $10.72. Xencor's Cyclically Adjusted PB Ratio for today is 0.75.

The historical rank and industry rank for Xencor's Cyclically Adjusted PB Ratio or its related term are showing as below:

XNCR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.7   Med: 2.43   Max: 4.48
Current: 0.7

During the past years, Xencor's highest Cyclically Adjusted PB Ratio was 4.48. The lowest was 0.70. And the median was 2.43.

XNCR's Cyclically Adjusted PB Ratio is ranked better than
64.38% of 671 companies
in the Biotechnology industry
Industry Median: 1.49 vs XNCR: 0.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xencor's adjusted book value per share data for the three months ended in Mar. 2025 was $8.995. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.72 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xencor Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Xencor's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Cyclically Adjusted PB Ratio Chart

Xencor Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.16 2.23 2.19

Xencor Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 1.88 1.95 2.19 0.99

Competitive Comparison of Xencor's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Xencor's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Cyclically Adjusted PB Ratio falls into.


;
;

Xencor Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Xencor's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.00/10.72
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Xencor's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=8.995/134.9266*134.9266
=8.995

Current CPI (Mar. 2025) = 134.9266.

Xencor Quarterly Data

Book Value per Share CPI Adj_Book
201506 4.006 100.684 5.368
201509 3.788 100.392 5.091
201512 4.006 99.792 5.416
201603 3.898 100.470 5.235
201606 5.095 101.688 6.760
201609 4.920 101.861 6.517
201612 6.742 101.863 8.930
201703 6.506 102.862 8.534
201706 6.432 103.349 8.397
201709 6.188 104.136 8.018
201712 6.733 104.011 8.734
201803 9.667 105.290 12.388
201806 9.301 106.317 11.804
201809 9.469 106.507 11.996
201812 9.269 105.998 11.799
201903 10.818 107.251 13.610
201906 10.757 108.070 13.430
201909 10.760 108.329 13.402
201912 10.425 108.420 12.974
202003 10.403 108.902 12.889
202006 9.974 108.767 12.373
202009 9.908 109.815 12.174
202012 9.891 109.897 12.144
202103 10.024 111.754 12.102
202106 11.094 114.631 13.058
202109 10.587 115.734 12.343
202112 12.358 117.630 14.175
202203 12.818 121.301 14.258
202206 12.438 125.017 13.424
202209 12.091 125.227 13.028
202212 12.125 125.222 13.065
202303 11.321 127.348 11.995
202306 11.203 128.729 11.742
202309 11.028 129.860 11.458
202312 10.849 129.419 11.311
202403 9.938 131.776 10.176
202406 9.136 132.554 9.300
202409 10.346 133.029 10.494
202412 9.645 133.157 9.773
202503 8.995 134.927 8.995

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xencor  (NAS:XNCR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Xencor Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor Business Description

Industry
Traded in Other Exchanges
Address
465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Executives
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604